Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

The conversation is about making topical finasteride using ethanol. The user is advised to use non-denatured or food-grade ethanol, as denatured ethanol may be harmful with prolonged skin exposure.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The user is considering cutting a 5mg finasteride pill into quarters to take 1.25mg daily due to concerns about side effects. They are also contemplating using 0.5mg of dutasteride instead.

Breezula (clascoterone) and Formula 82F (topical finasteride) are treatments for hair loss that block DHT differently; Breezula competes with DHT at the hormone receptor site without systemic effects, while 82F inhibits the enzyme that converts testosterone to DHT. Breezula may work for those who don't respond to finasteride and vice versa.

The post discusses diluting 100ml of 0.1% topical finasteride with 90ml of stemoxydine to create a 0.05% solution, aiming for a longer-lasting and potentially less side-effect-prone treatment. The user seeks feedback on this idea.

Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

JeremySoCa's DHT level was 29 ng/dl, considered low, and Estradiol was 26.1 pg/dl within the normal range. They are using topical finasteride for hair loss and had a thyroidectomy due to Graves' disease.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

A user is seeking a 15% Minoxidil solution without finasteride or azelaic acid, as they can no longer find it. Another user is curious about the results of using the 15% Minoxidil.

A user shared their 75-day progress using oral minoxidil, finasteride, ketoconazole shampoo, and dermastamping for retrograde alopecia, reporting significant improvement and increased body hair without side effects. They also discussed quitting smoking and the potential correlation between early beard growth and male pattern baldness.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

Mixing tretinoin with minoxidil for hair loss is discussed, with a recommendation for using 0.025% tretinoin.

The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.

The post discusses using a topical tincture containing zinc, azelaic acid, and other ingredients to inhibit 5 alpha-reductase activity for treating hair loss. The user plans to try this natural alternative before using finasteride or RU58841.

The conversation is about someone's hair improvement after 5.5 years on finasteride, with various users commenting on the results and discussing their own experiences with hair loss treatments. Some users can't see a difference, while others inquire about the dosage used.

Topical finasteride with hydroxypropyl chitosan shows significantly less serum absorption and minimal DHT reduction compared to oral finasteride. Users need the specific chitosan formulation to avoid side effects seen with regular ethanol+PG solutions.

People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.

A 21-year-old has been using a 0.5 mm dermaroller weekly with 5% Minoxidil for five months and Finasteride for three months to address hair loss. The conversation includes questions about the frequency of dermarolling.

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

A 25-year-old is using a nightly routine of topical finasteride 0.3% and minoxidil 6%, along with a derma roller and Nizoral shampoo, to address crown hair loss. The user reports no side effects and noticeable improvement over 2.5 months.

A user discusses their hair loss journey, starting with 5% minoxidil and nizoral, and now using DualGen-15 Plus with 15% minoxidil and 0.1% finasteride. They also use biotin, pumpkin seed oil, Pura D'or Professional shampoo, and derma rolling, noting some shedding and side effects.